{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-085479","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2025-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.211913+00:00","generated_at":"2026-05-19T10:44:55.200311+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Intellia shareholders elect three Class III directors and approve 2025 equity plan","bullets":["Elected William Chase, Georgia Keresty, and John M. Leonard as Class III directors for three-year terms ending 2028.","Approved the 2025 Equity Incentive Plan: 50.8M for, 13.6M against, 93.8K abstentions.","Ratified Deloitte & Touche as independent auditor for FY2025: 82.1M for, 497.8K against.","Advisory say-on-pay vote passed (45.8M for, 18.6M against); future votes will be held annually.","Broker non-votes were 18.3M on director elections, equity plan, and say-on-pay."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-085479","json":"https://secwatch.observer/filing/0000950170-25-085479.json","markdown":"https://secwatch.observer/filing/0000950170-25-085479.md","text":"https://secwatch.observer/filing/0000950170-25-085479.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025085479/0000950170-25-085479-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025085479/ntla-20250611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T10:44:55.200311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}